ABOUT US

Proxi Biotech was founded in 2018, based on research conducted at the Statens Serum Institute in Denmark, with a mission to contribute to global health by developing highly needed vaccines overcoming the urgent threat of antimicrobial resistance.


Our research and technology are led by world-class scientists with a strong passion and track record of turning lab scale research into effective vaccine products.  

PROJECTS & FUNDING

Proxi Biotech's BACTOVAC platform is a versatile toxoid antigen production technology developed to create and advance novel prophylactic and therapeutic vaccines. Our projects are collaborations with private and public partners in the vaccine development space. We focus on developing and bringing vaccine candidates through preclinical proof-of-concept in relevant animal models and advancing into early clinical phase. 

We have received numerous national and European non-dilutive grants for a total of ca. 880.000 EUR

TRANSVAC2 - 2022

Evaluation of safety, dose-finding and stability of CDIFFVAC, a superior toxoid-based vaccine against Clostridioides difficile infection

InnoBooster - 2022

Development of a new type of highly potent and safe toxoid-based vaccine against bacterial infections

TRANSVAC2 - 2020

Safety and immunogenicity of a CMS-adjuvanted, newly developed toxoid-based vaccine against C. difficile infection in non-rodent species

Eurostars - 2020

Next generation vaccines for multi-resistant bacteria

EIT Health Headstart - 2020

Next generation vaccines for multi-resistant bacteria

InnoBooster - 2019

Validation of a novel detoxification platform turning bacterial toxins into vaccine antigens

Business Acceleration academy - 2019

New method for creating toxoid-based vaccines 

PRESS COVERAGE & INTERNATIONAL AWARDS

FOLLOW OUR PROJECTS

unsplash